No Prescription |
 |
 | ||
|
Xergic Telfast |
|
| ||
No Prescription » Prescription Drugs 17 » Xergic Telfast Indications30 mg tablets: Relief of symptoms associated with seasonal allergic rhinitis in children aged 6 to 11 years.60 mg tablets: Relief of symptoms associated with allergic rhinitis in adults and children aged 12 years or older.120 mg tablets: Relief of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years or older.180 mg tablets: Relief of symptoms associated with seasonal allergic rhinitis or urticaria in adults and children aged 12 years or older.Dosage And AdministrationChildren aged 6 to 11 years:The recommended dosage of XERGIC 30 mg tablets is one tablet twice daily when required.Adults and children aged 12 years or older: 60 mg tablets: The recommended dosage of XERGIC is one 60 mg tablet twice daily when required.120 mg and 180 mg tablets: The recommended dosage of XERGIC 120 mg and 180 mg tablets is one tablet once daily when required. Dosage adjustment is not required in the elderly or in patients with hepatic or renal impairment. Buy Xergic Telfast and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Xergic Telfast: Product Type: Prescription Drugs 17 Xergic ( Telfast Allegra Generic Fexofenadine ) Xergic (Telfast Allegra Generic Fexofenadine) Telfast Allegra Generic Fexofenadine 120mg Telfast Allegra Generic Fexofenadine Xergic
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
